Physician profile
Thang Le
NPI 1760559819
$7,026.21
in general payments reported to CMS, 2019-2025
26 companies · $1,167 in 2025
The $1,167 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,788 · 2020: $682 · 2021: $936 · 2022: $434 · 2023: $704 · 2024: $1,316 · 2025: $1,167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,186.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,208.00 | 2019-2025 | Krystexxa, Evenity, Otezla |
| Abbvie INC. | $991.81 | 2019-2025 | |
| Glaxosmithkline, LLC. | $818.32 | 2019-2025 | Benlysta |
| Novartis Pharmaceuticals Corporation | $768.55 | 2019-2025 | |
| Pfizer INC. | $607.12 | 2019-2025 | |
| Janssen Biotech, INC. | $545.04 | 2019-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $470.39 | 2019-2025 | Orencia |
| Genentech USA, INC. | $372.04 | 2019-2020 | |
| Horizon Therapeutics Plc | $194.56 | 2021-2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $187.15 | 2021-2025 | Lupkynis |
| US Oncology Corporate, INC. | $173.84 | 2024 | |
| Ucb, INC. | $155.24 | 2020-2025 | Bimzelx, Cimzia |
| Fresenius Kabi USA, LLC | $90.88 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.99 | 2020-2024 | Cyltezo, Ofev |
| Medexus Pharma, INC. | $57.75 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $51.43 | 2019 | |
| Ani Pharmaceuticals, INC. | $50.00 | 2024 | Purified Cortrophin Gel |
| Radius Health, INC. | $40.06 | 2020-2023 | |
| Mallinckrodt Enterprises LLC | $28.65 | 2019 | |
| Alexion Pharmaceuticals, INC. | $23.85 | 2019 | |
| Sanofi-Aventis U.S. LLC | $20.36 | 2019 | |
| Depuy Synthes Sales INC. | $19.98 | 2024 | Orthovisc, Monovisc |
| Lilly USA, LLC | $19.11 | 2019 | |
| Organon LLC | $18.23 | 2022 | |
| Collegium Pharmaceutical, INC. | $17.42 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thang Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.